{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:38:32Z","timestamp":1784774312817,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pcad.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:42:03Z","timestamp":1769067723000},"page":"129-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The new life of myectomy in the era of myosin inhibitors"],"prefix":"10.1016","volume":"95","author":[{"given":"Giovanni","family":"Quarta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Simona","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Bonacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Giuseppe","family":"Cerillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Iacovoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Pentiricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2026.01.004_bb0005","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"2023","key":"10.1016\/j.pcad.2026.01.004_bb0010","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"2024","key":"10.1016\/j.pcad.2026.01.004_bb0015","first-page":"e1239","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2026.01.004_bb0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.mayocp.2024.07.013","article-title":"Hypertrophic cardiomyopathy: state of the art","volume":"100","author":"Ommen","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2026.01.004_bb0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2026.01.004_bb0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2217\/fca-2023-0056","article-title":"Obstructive hypertrophic cardiomyopathy: a review of new therapies","volume":"19","author":"Mehra","year":"2023","journal-title":"Future Cardiol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0040","first-page":"833","article-title":"Interventions in hypertrophic obstructive cardiomyopathy","volume":"40","author":"Ding","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","article-title":"Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy","volume":"85","author":"Smedira","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0050","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2026.01.004_bb0055","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"EXPLORER-HCM study investigators, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.pcad.2026.01.004_bb0060","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2026.01.004_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101412","article-title":"Optimal medical therapy versus septal reduction therapy","volume":"4","author":"Beloy","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.pcad.2026.01.004_bb0070","doi-asserted-by":"crossref","unstructured":"M. Woodland, R.A. Al-Horani, New era: Mavacamten for obstructive hypertrophic cardiomyopathy, Cardiovasc Hematol Agents Med Chem 21 (n.d.) 78\u201383. doi:https:\/\/doi.org\/10.2174\/1871525721666221019095218.","DOI":"10.2174\/1871525721666221019095218"},{"key":"10.1016\/j.pcad.2026.01.004_bb0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/hrt.22.3.403","article-title":"Obstructive cardiomyopathy simulating aortic stenosis","volume":"22","author":"Goodwin","year":"1960","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2026.01.004_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000658-196108000-00003","article-title":"Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic Ventriculomyotomy","volume":"154","author":"Morrow","year":"1961","journal-title":"Ann Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/01.CIR.37.4.589","article-title":"Operative treatment in idiopathic hypertrophic subaortic stenosis","volume":"37","author":"Morrow","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2026.01.004_bb0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/1010-7940(94)90044-2","article-title":"Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles","volume":"8","author":"Schoendube","year":"1994","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1540-8191.1991.tb00560.x","article-title":"Surgical techniques for hypertrophic left ventricular obstructive myopathy including mitral valve plication","volume":"6","author":"Cooley","year":"1991","journal-title":"J Card Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0100","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","article-title":"Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy","volume":"66","author":"Ferrazzi","year":"2015","journal-title":"JACC"},{"key":"10.1016\/j.pcad.2026.01.004_bb0105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12265-009-9153-2","article-title":"The left ventricular outflow in hypertrophic cardiomyopathy: from structure to function","volume":"2","author":"Yacoub","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.pcad.2026.01.004_bb0110","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal Myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC expert panel","volume":"180","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0115","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.jtcvs.2017.10.054","article-title":"Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy","volume":"155","author":"Hang","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1073\/pnas.0909468107","article-title":"Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers","volume":"107","author":"Stewart","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pcad.2026.01.004_bb0125","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63703","article-title":"To lie or not to lie: super-relaxing with myosins","volume":"10","author":"Nag","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.pcad.2026.01.004_bb0130","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pcad.2026.01.004_bb0135","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1161\/CIRCULATIONAHA.121.053575","article-title":"Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy","volume":"144","author":"Ranjbarvaziri","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2026.01.004_bb0140","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/cvr\/cvy147","article-title":"Metabolic changes in hypertrophic cardiomyopathies: scientific update from the working Group of Myocardial Function of the European Society of Cardiology","volume":"114","author":"van der Velden","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2026.01.004_bb0145","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pcad.2026.01.004_bb0150","doi-asserted-by":"crossref","first-page":"618a","DOI":"10.1016\/j.bpj.2024.11.3188","article-title":"BPS2025 - long-term effect of Mavacamten impact force and sarcomere density in a MYBPC3 iPSC-cardiomyocyte model of hypertrophic cardiomyopathy","volume":"124","author":"Langione","year":"2025","journal-title":"Biophys J"},{"key":"10.1016\/j.pcad.2026.01.004_bb0155","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/psp4.13197","article-title":"Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration","volume":"13","author":"Chang","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0160","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of Aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.pcad.2026.01.004_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2026.01.004_bb0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0175","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"For the VALOR-HCM investigators, mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2026.01.004_bb0180","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2026.01.004_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1026440","article-title":"Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies","volume":"9","author":"Porcari","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2026.01.004_bb0190","article-title":"A surgeon\u2019s toolkit for mitral valve\u2013induced left ventricular outflow tract obstruction with minimal septal hypertrophy","volume":"0","author":"Maigrot","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0195","doi-asserted-by":"crossref","first-page":"30317","DOI":"10.21037\/acs.2017.06.04","article-title":"Current state of the art and future of myectomy","volume":"6","author":"Yacoub","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0200","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jtcvs.2009.10.045","article-title":"Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation","volume":"140","author":"Kwon","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11748-018-0915-0","article-title":"Management of systolic anterior motion of the mitral valve: a mechanism-based approach","volume":"66","author":"Manabe","year":"2018","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0210","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s10554-024-03242-4","article-title":"Hypertrophic obstructive cardiomyopathy-left ventricular outflow tract shapes and their hemodynamic influences applying CMR","volume":"40","author":"Mayr","year":"2024","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2026.01.004_bb0215","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtcvs.2024.04.016","article-title":"Efficacy and safety of a transaortic approach to midventricular and apical septal myectomy","volume":"168","author":"Maigrot","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0220","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.athoracsur.2020.05.182","article-title":"Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction","volume":"111","author":"Sun","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0225","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.athoracsur.2022.05.062","article-title":"Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy","volume":"114","author":"Holst","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0230","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pcad.2023.06.001","article-title":"Patient reported outcomes in obstructive hypertrophic cardiomyopathy undergoing myectomy: results from SPIRIT-HCM study","volume":"80","author":"Tower-Rader","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2026.01.004_bb0235","article-title":"Procedural volume and outcomes after septal reduction therapies in hypertrophic obstructive cardiomyopathy","volume":"13","author":"Patel","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2026.01.004_bb0240","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/eurheartj\/ehr006","article-title":"Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients","volume":"32","author":"Maron","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2026.01.004_bb0245","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacc.2023.05.052","article-title":"First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy","volume":"82","author":"Fang","year":"2023","journal-title":"JACC"},{"key":"10.1016\/j.pcad.2026.01.004_bb0250","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1097\/JS9.0000000000001797","article-title":"Transapical beating heart septal myectomy learning curve and training of future surgeons: an observational study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.pcad.2026.01.004_bb0255","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.124.015044","article-title":"Transapical beating-heart septal myectomy for obstructive hypertrophic cardiomyopathy: lessons learned after the learning curve period","volume":"18","author":"Fang","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2026.01.004_bb0260","doi-asserted-by":"crossref","DOI":"10.1161\/circ.148.suppl_1.12408","article-title":"Abstract 12408: response to mavacamten by sarcomere gene mutation status in EXPLORER-HCM","volume":"148","author":"Ho","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2026.01.004_bb0265","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.mayocp.2023.11.019","article-title":"Genotype influences mavacamten responsiveness in obstructive hypertrophic cardiomyopathy","volume":"99","author":"Giudicessi","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2026.01.004_bb0270","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014095","article-title":"Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system","volume":"9","author":"Thomas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2026.01.004_bb0275","doi-asserted-by":"crossref","unstructured":"F. Pelliccia, O. Alfieri, P. Calabr\u00f2, F. Cecchi, P. Ferrazzi, F. Gragnano, J.P. Kaski, G. Limongelli, M. Maron, C. Rapezzi, H. Seggewiss, M.H. Yacoub, I. Olivotto, Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: towards the HCM Heart Team, Int J Cardiol 304 (2020) 86\u201392. doi:https:\/\/doi.org\/10.1016\/j.ijcard.2020.01.021.","DOI":"10.1016\/j.ijcard.2020.01.021"},{"key":"10.1016\/j.pcad.2026.01.004_bb0280","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.01.004_bb0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"REDWOOD-HCM steering committee and investigators. Phase 2 study of Aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2026.01.004_bb0290","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2026.01.004_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.040","article-title":"Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: 48-week results from FOREST-HCM","volume":"13","author":"Saberi","year":"2025","journal-title":"JACC Heart Fail"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:03:04Z","timestamp":1781571784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062026000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"alternative-id":["S0033062026000046"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2026.01.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new life of myectomy in the era of myosin inhibitors","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}